Mylan Japan Establishes New Marketing Team To Expand Japanese Market
This article was originally published in PharmAsia News
The world's third-largest generic drug maker, U.S.-based Mylan Pharmaceutical is strengthening its oncology products business in Japan. Mylan Japan assembled a team of 30 staff whose experience ranges from marketing to research and assigned them to promote anticancer drugs and infection treatments to medical facilities nationwide. Consisting of 20 medical representatives from 11 branch offices all over Japan and 10 scientific staff, the so called M-TAC team will focus on visiting physicians at combined diagnostic procedure hospitals. The payment system at these DPC hospitals has made economic sense for using generic drugs. (Click here for more - Japanese language)
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.